Allosteric inhibition of hypoxia inducible factor-2 with small molecules

Nature Chemical Biology

Volumn 9, Issue 4, 2013, Pages 271-276

  Scheuermann, Thomas H ^a,b   Li, Qiming ^a   Ma, He Wen ^a   Key, Jason ^a,b   Zhang, Lei ^a   Chen, Rui ^a,c   Garcia, Joseph A ^a,c   Naidoo, Jacinth ^a   Longgood, Jamie ^a   Frantz, Doug E ^a   Tambar, Uttam K ^a   Gardner, Kevin H ^a,b   Bruick, Richard K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ARTICLE; BETA SHEET; CONFORMATIONAL TRANSITION; DIMERIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; STOICHIOMETRY;

ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BINDING SITES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS; LIGANDS; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES;

EID: 84875443909     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1185     Document Type: Article

References (55)

1. Semenza, G.L. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207-214 (2012).
2. Xia, X. et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. USA 106, 4260-4265 (2009).
3. Schödel, J. et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207 - e217 (2011).
4. Majmundar, A.J., Wong, W.J. & Simon, M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309 (2010).
5. Greer, S.N., Metcalf, J.L., Wang, Y. & Ohh, M. The updated biology of hypoxia-inducible factor. EMBO J. 31, 2448-2460 (2012).
6. Kondo, K., Kim, W.Y., Lechpammer, M. & Kaelin, Jr. W.G. Inhibition of HIF2? is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).
7. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
8. Maranchie, J.K. et al. The contribution of VHL substrate binding and HIF1-? to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002).
9. Erbel, P.J., Card, P.B., Karakuzu, O., Bruick, R.K. & Gardner, K.H. Structural basis for PAS domain heterodimerization in the basic helix-loop-helix - PAS transcription factor hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA 100, 15504-15509 (2003).
10. Yang, J. et al. Functions of the Per/ARNT/Sim (PAS) domains of the hypoxia inducible factor (HIF). J. Biol. Chem. 280, 36047-36054 (2005).
11. Partch, C.L., Card, P.B., Amezcua, C.A. & Gardner, K.H. Molecular basis of coiled coil coactivator recruitment by the aryl hydrocarbon receptor nuclear translocator (ARNT). J. Biol. Chem. 284, 15184-15192 (2009).
12. Partch, C.L. & Gardner, K.H. Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proc. Natl. Acad. Sci. USA 108, 7739-7744 (2011).
13. Henry, J.T. & Crosson, S. Ligand-binding PAS domains in a genomic, cellular, and structural context. Annu. Rev. Microbiol. 65, 261-286 (2011).
14. Harper, S.M., Neil, L.C. & Gardner, K.H. Structural basis of a phototropin light switch. Science 301, 1541-1544 (2003).
15. Wells, J.A. & McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007).
16. Koehler, A.N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 14, 331-340 (2010).
17. Key, J., Scheuermann, T.H., Anderson, P.C., Daggett, V. & Gardner, K.H. Principles of ligand binding within a completely buried cavity in HIF2? PAS-B. J. Am. Chem. Soc. 131, 17647-17654 (2009).
18. Scheuermann, T.H. et al. Artificial ligand binding within the HIF2? PAS-B domain of the HIF2 transcription factor. Proc. Natl. Acad. Sci. USA 106, 450-455 (2009).
19. Qing, G. & Simon, M.C. Hypoxia inducible factor-2?: A critical mediator of aggressive tumor phenotypes. Curr. Opin. Genet. Dev. 19, 60-66 (2009).
20. Morris, M.R. et al. Mutation analysis of hypoxia-inducible factors HIF1? and HIF2? in renal cell carcinoma. Anticancer Res. 29, 4337-4343 (2009).
21. Kaelin, Jr. W.G. Treatment of kidney cancer: Insights provided by the VHL tumor-suppressor protein. Cancer 115, 2262-2272 (2009).
22. Shen, C. et al. Genetic and functional studies implicate HIF1? as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222-235 (2011).
23. Amezcua, C.A., Harper, S.M., Rutter, J. & Gardner, K.H. Structure and interactions of PAS kinase N-terminal PAS domain: Model for intramolecular kinase regulation. Structure 10, 1349-1361 (2002).
24. Rogers, J.L. et al. Development of inhibitors of the PAS-B domain of the HIF-2? transcription factor. J. Med. Chem. 10.1021/jm301847z (30 January 2013).
25. Krieg, M. et al. Up-regulation of hypoxia-inducible factors HIF-1? and HIF-2? under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-5443 (2000).
26. Dioum, E.M. et al. Regulation of hypoxia-inducible factor 2? signaling by the stress-responsive deacetylase sirtuin 1. Science 324, 1289-1293 (2009).
27. Scortegagna, M. et al. HIF-2? regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105, 3133-3140 (2005).
28. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
29. Keith, B., Johnson, R.S. & Simon, M.C. HIF1? and HIF2?: Sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9-22 (2012).
30. Franovic, A., Holterman, C.E., Payette, J. & Lee, S. Human cancers converge at the HIF-2? oncogenic axis. Proc. Natl. Acad. Sci. USA 106, 21306-21311 (2009).
31. Holmquist-Mengelbier, L. et al. Recruitment of HIF-1? and HIF-2? to common target genes is differentially regulated in neuroblastoma: HIF-2? promotes an aggressive phenotype. Cancer Cell 10, 413-423 (2006).
32. Pietras, A. et al. HIF-2? maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc. Natl. Acad. Sci. USA 106, 16805-16810 (2009).
33. Mazumdar, J. et al. HIF-2? deletion promotes Kras-driven lung tumor development. Proc. Natl. Acad. Sci. USA 107, 14182-14187 (2010).
34. Ivan, M. et al. HIF? targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292, 464-468 (2001).
35. Jaakkola, P. et al. Targeting of HIF-? to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
36. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002).
37. Lando, D., Peet, D.J., Whelan, D.A., Gorman, J.J. & Whitelaw, M.L. Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science 295, 858-861 (2002).
38. Kaelin, W.G. Von Hippel-Lindau disease. Annu. Rev. Pathol. 2, 145-173 (2007).
39. Halavaty, A.S. & Moffat, K. N- and C-terminal flanking regions modulate light-induced signal transduction in the LOV2 domain of the blue light sensor phototropin 1 from Avena sativa. Biochemistry 46, 14001-14009 (2007).
40. Park, E.J. et al. Targeting the PAS-A domain of HIF-1? for development of small molecule inhibitors of HIF-1. Cell Cycle 5, 1847-1853 (2006).
41. Lee, K. et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. USA 106, 17910-17915 (2009).
42. Semenza, G.L. HIF-1: Upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20, 51-56 (2010).
43. Johnson, B.A. & Blevins, R.A. NMRView: A computer program for the visualization and analysis of NMR data. J. Biomol. NMR 4, 603-614 (1994).
44. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
45. Adams, P.D. et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
46. Schüttelkopf, A.W. & van Aalten, D.M. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).
47. Emsley, P. & Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
48. Chen, V.B. et al. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
49. Winn, M.D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
50. Martí-Renom, M.A. et al. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291-325 (2000).
51. Bookout, A.L. & Mangelsdorf, D.J. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal. 1, e012 (2003).
52. Scheuermann, T.H., Yang, J., Zhang, L., Gardner, K.H. & Bruick, R.K. Hypoxia-inducible factors Per/ARNT/Sim domains: Structure and function. Methods Enzymol. 435, 3-24 (2007).
53. Chen, R., Dioum, E.M., Hogg, R.T., Gerard, R.D. & Garcia, J.A. Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner. J. Biol. Chem. 286, 13869-13878 (2011).
54. McNaney, C.A. et al. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev. Technol. 6, 121-129 (2008).
55. Drexler, D.M. et al. An automated high throughput liquid chromatography-mass spectrometry process to assess the metabolic stability of drug candidates. Assay Drug Dev. Technol. 5, 247-264 (2007).